Australian (ASX) Stock Market Forum

IMU - Imugene Limited

Looks like IMU will come out with some strong positives - speculating on its QBR published on 31 Oct.



1730642566704.png
 

Attachments

  • Quarterly-ActivitiesAppendix-4C-Cash-Flow-Report.PDF
    461.5 KB · Views: 1
2024 CY Comp - Nov update.

IMU has been very disappointing and is the worst pick out of my 4 selections. Down 65% so far this year, nearly 12% down this month. It's knocked my average around a lot.

I can't see Dec making much difference to the return now. As I said before, very disappointing.
 
Another recurring disappointment for my portfolio that tests my patience on the thesis that good biotech research takes time and money to reap outsized returns. IMU has secured another $46M in convertible notes and expects another $11M in FY 2023 R&D rebates. Will this be enough to bring one of their clinical trial candidates to commercialisation or outcomes good enough to attract M&A attention? That's the gamble for me.
 
Top